Drugs / iC9-CAR.B7-H3 T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06305299 | Jul 2024 → Apr 2036 expected | malignant epithelial tumor of ovary | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06158139 | Jul 2024 → Apr 2028 expected | pancreatic ductal adenocarcinoma, refractory malignant neoplasm | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06347068 | Jun 2024 → May 2028 expected | refractory malignant neoplasm, triple-negative breast carcinoma | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iC9.CAR.B7-H3 T cells | “T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) treatment is experimental and has not been approved by the Food and Drug Administration.” NCT06347068 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T cells (CAR-T) cells” NCT06158139 ↗ |
| Route | Intravenous | “iC9-CAR.B7-H3 T cell product will be administered via intravenous injection” NCT06158139 ↗ |